Study of mycophenolate mofetil and lamivudine in treatment of hepatitis b virus associated glomerulonephritis

Wu Shengbin,Wang Yingdeng,Xu Ying
DOI: https://doi.org/10.3969/j.issn.1008-8849.2008.30.004
2008-01-01
Abstract:Objective It is to observe the clinical efficacy and the adverse effects of mycophenolate mofetil(MMF) combined with lamivudine in treatment of patients with hepatitis b virus associated glomerulonephritis(HBV-GN).Methods35 patients with HBV-GN were treated with MMF combined with lamivudine orally.24h excretion of proteinuria,serum albumin,liver function,renal function,blood fat and hepatitis b virus DNA(HBV-DNA) were assessed.The adverse effects were measured regularly.Results 24 h proteinuria excretion was significantly reduced by the treatment of mycophenolate mofetil and lamivudine(P<0.05).The serum albumin was significantly improved(P<0.05).Serum creatinine were remarkably reduced(P<0.05). The reproduction of HBV-DNA did not increase.The total effective rate was 86% after 12 months treatment,while 20 of 35 cases achieved complete remission(57%) and 10 cases partial remission(29%).There were no serious adverse effects during the period of treatment.Conclusion The preliminary investigation demonstrates that MMF combined with lamivudine was effective and safe without increasing the risk of occurrence rate of HBV-DNA reproduction.
What problem does this paper attempt to address?